FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
Human Drugs

FDA Accepts Tagrisso sNDA, Grants Priority Review

FDA accepts an sNDA for AstraZenecas Tagrisso cancer drug and will give it priority review.

Medical Devices

Ezra Artificial Intelligence Cleared For Prostate MRI Scans

FDA clears an Ezra 510(k) for its artificial intelligence and its use in assisting radiologists in their analysis of prostate MRI scans.

Medical Devices

FDA Posts Device Development Tool on Cybersecurity

FDAs Medical Device Development Tools program lists an agency-qualified tool that medical device sponsors can use in developing and evaluating medical...

FDA General

Latest FDA Warning Letters

FDA releases its latest batch of Warning Letters that include Medoz Pharmacy of Polk and RLC Labs.

Federal Register

CDRH Web Site on Priority Guidance Development

Federal Register notice: FDA announces the Web site location where it will post two lists outlining guidance documents that CDRH intends to publish in...

Federal Register

Nonvoting Industry Reps for Device Panels Sought

Federal Register notice: FDA seeks industry organizations interested in participating in selecting nonvoting industry representatives to serve on cert...

Medical Devices

Ossiofiber Compression Screw Portfolio Cleared

FDA clears an Ossio 510(k) for its Ossiofiber Compression Screw Portfolio for alignment maintenance and fixation of bone fractures.

Human Drugs

FDA Gives Full Approval to Venclexta

FDA grants full approval for AbbVie and Roches Venclexta (venetoclax) in combination with azacitidine, or decitabine, or low-dose cytarabine for treat...

FDA General

Update on FDAs Technology Modernization Plan

FDA says that under its technology modernization plan it is accelerating the implementation of a software defined network and adoption of other design...

Medical Devices

CDRH Discussion Paper on Communicating Cybersecurity Issues

FDA seeks feedback on a discussion paper entitled Communicating Cybersecurity Vulnerabilities to Patients: Considerations for a Framework.